|
OSBPL9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.86830012466532E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.57239999909464E-08 |
| Normal-vs-Stage2 |
1.048720E-04 |
| Normal-vs-Stage3 |
5.86830000148808E-08 |
| Normal-vs-Stage4 |
1.46610000029135E-07 |
| Stage1-vs-Stage2 |
9.202000E-01 |
| Stage1-vs-Stage3 |
1.225170E-01 |
| Stage1-vs-Stage4 |
1.220840E-01 |
| Stage2-vs-Stage3 |
3.791800E-01 |
| Stage2-vs-Stage4 |
2.710000E-01 |
| Stage3-vs-Stage4 |
7.943800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.43639988792188E-10 |
| Normal-vs-AfricanAmerican |
8.880300E-03 |
| Normal-vs-Asian |
1.677810E-03 |
| Caucasian-vs-AfricanAmerican |
1.940380E-01 |
| Caucasian-vs-Asian |
6.191600E-02 |
| AfricanAmerican-vs-Asian |
9.295200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.39779999966494E-07 |
| Normal-vs-Female |
7.50620010592229E-10 |
| Male-vs-Female |
5.987200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.91159999951962E-07 |
| Normal-vs-Age(41-60Yrs) |
1.86409999658466E-08 |
| Normal-vs-Age(61-80Yrs) |
1.13139999591283E-08 |
| Normal-vs-Age(81-100Yrs) |
8.430800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.511600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.375370E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.148570E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.397200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.504600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.711800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.091400E-01 |
| Classical-VS-Follicular |
1.942560E-01 |
| Classical-VS-Other |
8.159400E-01 |
| Classical-VS-Normal |
2.64299999996886E-06 |
| Tall-VS-Follicular |
1.586630E-01 |
| Tall-VS-Other |
5.001800E-01 |
| Tall-VS-Normal |
1.93003999999775E-05 |
| Follicular-VS-Other |
8.527200E-01 |
| Follicular-VS-Normal |
3.832200E-04 |
| Other-VS-Normal |
8.166400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.79860000226739E-08 |
| Normal-vs-N1 |
7.58330000016905E-07 |
| N0-vs-N1 |
4.602200E-01 |
|
|
